Abstract
Existing methodology for the design of Phase I–II studies has been intended to search for the optimal regimen, based on a tradeoff between toxicity and efficacy, from a set of regimens comprised of doses of a new agent. The underlying assumptions guiding allocation are that the dose–toxicity curve is monotonically increasing, and that the dose–efficacy curve either plateaus or decreases beyond an intermediate dose. This article considers the problem of designing Phase I—II studies that violate these assumptions for both outcomes. The motivating application studies regimens that are not defined by doses of a new agent, but rather a peptide vaccine plus novel adjuvants for the treatment of melanoma. All doses of each adjuvant are fixed, and the regimens vary by the number and selection of adjuvants. This structure produces regimen–toxicity curves that are partially ordered, and regimen–efficacy curves that may deviate from a plateau or unimodal shape. Application of a Bayesian model-based design is described in determining the optimal biologic regimen, based on bivariate binary measures of toxicity and biologic activity. A simulation study of the design’s operating characteristics is conducted, and its versatility in handling other Phase I–II problems is discussed.
Similar content being viewed by others
References
Yuan Y, Nguyen HQ, Thall PF (2016) Bayesian designs for phase I-II clinical trials. Chapman and Hall/CRC Press, New York
O’Quigley J, Hughes MD, Fenton T (2001) Dose-finding designs for HIV studies. Biometrics 57:1018–1029
Slingluff CL Jr, Petroni GR, Olson W, Smolkin ME, Chianese-Bullock KA, Mauldin IS et al (2016) A randomized pilot trial testing the safety and immunologic effects of MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites. Cancer Immunol Immunother 65:25–36
Cai C, Yuan Y, Ji Y (2014) A bayesian dose finding design for oncology clinical trials of combinational biological agents. J R Stat Soc Ser C Appl Stat 63:159–173
Guo B, Li Y (2015) Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering. Stat Med 34:859–875
Mozgunov P, Jaki T (2018) An information theoretic phase I-II design for molecularly targeted agents that does not require an assumption of monotonicity. J R Stat Soc Ser C Appl Stat 68(2):347–367
Wages NA, Slingluff CL Jr, Petroni GR (2015) A phase I-II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma. Contemp Clin Trials 41:172–179
Wages NA, Slingluff CL Jr, Petroni GR (2017) Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies. Ann Oncol 28:697–701
Wages NA, Portell CA, Williams ME, Conaway MR, Petroni GR (2017) Implementation of a model-based design in a phase 1b study of combined targeted agents. Clin Cancer Res 23:7158–7164
Yin G, Yuan Y (2009) Bayesian model averaging continual reassessment method in phase I clinical trials. J Am Stat Assoc 104:954–968
O’Quigley J, Conaway MR (2011) Extended model-based designs for more complex phase I clinical trials. Stat Med 30:2062–69
Wages NA, Tait C (2014) Seamless phase I-II adaptive design for oncology trials of molecularly targeted agents. J Biopharm Stat 25:903–920
Cheung YK (2011) Dose finding by the continual reassessment method. Chapman and Hall/CRC Press, New York
Berry SM, Carlin BP, Lee JJ, Muller P (2011) Bayesian adaptive methods for clinical trials. Chapman and Hall/CRC Press, New York
Thall PF, Nguyen HQ (2012) Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomes. J Biopharm Stat 22:785–801
Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB et al (2011) Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 29:2924–2932
O’Quigley J, Pepe M, Fisher L (1990) Continual reassessment method: a practical design for Phase I clinical trials in cancer. Biometrics 46:33–48
Lee SM, Cheung YK (2009) Model calibration in the continual reassessment method. Clin Trials 6:227–238
Core Team R (2019) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria https://www.R-project.org/
Cheung YK (2019) dfcrm: dose-finding by the continual reassessment method. R package version (2-2):1 https://CRAN.R-project.org/package=dfcrm
Wages NA (2019) pocrm: dose finding in drug combination phase I trials using PO-CRM. R package version 12 https://CRAN.R-project.org/package=pocrm
Lee SM, Cheung YK (2011) Calibration of prior variance in the Bayesian continual reassessment method. Stat Med 30:2081–2089
O’Quigley J, Shen LZ (1996) Continual reassessment method: a likelihood approach. Biometrics 52:673–684
Zhang J, Braun TM, Taylor JMG (2013) Adaptive prior variance calibration in the Bayesian continual reassessment method. Stat Med 32:2221–2234
Naylor J, Smith A (1982) Applications of a method for the efficient computation of posterior distributions. J R Stat Soc Ser C Appl Stat 31:214–225
Paoletti X, Ezzalfani M, Le Tourneau C (2015) Statistical controversies in clinical research: requiem for the 3+3 design for phase I trials. Ann Oncol 26:1808–1812
Iasonos A, O’Quigley J (2014) Adaptive dose-finding studies: a review of model-guided phase I clinical trials. J Clin Oncol 32:2505–2511
Nie L, Rubin EH, Mehrotra N et al (2016) Rendering the 3+3 design to rest: more efficient approaches to oncology dose-finding trials in the era of targeted therapy. Clin Cancer Res 22:2623–2629
Cunanan K, Koopmeniners JK (2014) Evaluating the performance of copula models in phase I-II clinical trials under model misspecification. BMC Med Res Methodol 14:51
Liu S, Johnson VE (2016) A robust Bayesian dose-finding design for phase I-II clinical trials. Biostatistics 17:249–263
Iasonos A, Gönen M, Bosl GJ (2015) Scientific review of phase i protocols with novel dose-escalation designs: how much information is needed? J Clin Oncol 33:2221–2225
Petroni GR, Wages NA, Paux G, Dubois F (2017) Implementation of adaptive methods in early-phase clinical trials. Stat Med 36:215–224
Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C et al (2007) Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 13:6386–6395
Acknowledgements
Dr. Wages is supported by the National Institute of Health Grant K25CA181638. The authors would like to thank the Editor and two reviewers for their comments that lead to an improved manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wages, N.A., Slingluff, C.L. Flexible Phase I–II Design for Partially Ordered Regimens with Application to Therapeutic Cancer Vaccines. Stat Biosci 12, 104–123 (2020). https://doi.org/10.1007/s12561-019-09245-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12561-019-09245-3